No abstract available
Keywords:
COVID-19; bradycardia; critical illness; humans; lopinavir; ritonavir.
MeSH terms
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / pharmacokinetics
-
Betacoronavirus / drug effects*
-
Betacoronavirus / pathogenicity
-
Bradycardia / chemically induced*
-
Bradycardia / diagnostic imaging
-
Bradycardia / physiopathology
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Drug Combinations
-
Female
-
Heart Rate / drug effects*
-
Humans
-
Intensive Care Units*
-
Lopinavir / adverse effects*
-
Lopinavir / pharmacokinetics
-
Male
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
Prospective Studies
-
Risk Assessment
-
Risk Factors
-
Ritonavir / adverse effects*
-
Ritonavir / pharmacokinetics
-
SARS-CoV-2
-
Time Factors
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Drug Combinations
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
Ritonavir